ASCO Leaders Endorse Long-Term Use Of Revlimid And Rituxan To Prevent Relapse
This article was originally published in The Pink Sheet Daily
Executive Summary
Preview of upcoming American Society of Clinical Oncology conference highlights strong progression-free survival results, but overall survival benefit remains to be proven.